CLRB Stock Price, Cellectar Biosciences Quote, Chart

Market Summary

USD3.34+0.18

Market Closed

5.70%

CLRB Stock Price

View Fullscreen

CLRB RSI Chart

CLRB Valuation

Market Cap

107.8M

Price/Earnings (Trailing)

-2.84

Price/Sales (Trailing)

44.09

EV/EBITDA

-2.59

Price/Free Cashflow

-3.24

CLRB Price/Sales (Trailing)

CLRB Profitability

EBT Margin

-999.35%

Return on Equity

2.8K%

Return on Assets

-314.55%

Free Cashflow Yield

-30.85%

CLRB Fundamentals

CLRB Revenue

Revenue (TTM)

2.9M

CLRB Earnings

Earnings (TTM)

-38.0M

Earnings Growth (Yr)

-3.24%

Earnings Growth (Qtr)

45.76%

Breaking Down CLRB Revenue

Last 7 days

10.6%

Last 30 days

-16.3%

Last 90 days

-11.2%

Trailing 12 Months

121.2%

How does CLRB drawdown profile look like?

CLRB Financial Health

Current Ratio

0.81

Debt/Equity

-2.8

Debt/Cashflow

-8.53

CLRB Investor Care

Shares Dilution (1Y)

231.20%

Diluted EPS (TTM)

-3.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2015	3.8M	3.5M	3.2M	2.9M
2014	4.8M	4.5M	4.3M	4.1M
2013	0	0	0	5.0M
2011	1.2M	2.1M	3.1M	4.0M
2010	0	0	0	200.0K
2009	0	0	0	63.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cellectar Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 08, 2023	shustov andrei	acquired	-	-	47,856	senior vice president, medical
Dec 08, 2023	lea darrell shane	acquired	-	-	39,599	chief commercial officer
Dec 08, 2023	kolean chad j	acquired	-	-	42,554	chief financial officer
Dec 08, 2023	longcor jarrod	acquired	-	-	42,927	chief operating officer
Dec 08, 2023	caruso james v	acquired	-	-	40,596	president and ceo
Sep 14, 2021	swirsky douglas j	bought	26,000	1.04	25,000	-
Sep 03, 2021	driscoll frederick w	bought	20,244	1.0426	19,417	-
Mar 04, 2021	caruso james v	bought	8,658	1.6978	5,100	president and ceo
Dec 28, 2020	elefant dov	bought	9,999	1.35	7,407	chief financial officer
Dec 28, 2020	longcor jarrod	bought	40,000	1.35	29,630	chief business officer

Which funds bought or sold CLRB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Rosalind Advisors, Inc.	reduced	-69.01	-3,082,190	2,473,480	2.31%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	14,000	14,000	-%
Apr 23, 2024	BFSG, LLC	new	-	3,980	3,980	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	143,380	143,380	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	new	-	119,400	119,400	-%
Mar 11, 2024	VANGUARD GROUP INC	added	174	873,271	1,337,600	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	5.00	111	-%
Feb 15, 2024	Coastal Bridge Advisors, LLC	new	-	63,710	63,710	0.02%
Feb 15, 2024	Nantahala Capital Management, LLC	new	-	7,482,200	7,482,200	0.22%

Are Funds Buying or Selling CLRB?

Are funds buying CLRB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLRB

No. of Funds

Unveiling Cellectar Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	9.9%	3,305,936	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	3,229,903	SC 13G
Feb 14, 2024	rosalind advisors, inc.	9.9%	1,488,400	SC 13G/A
Feb 14, 2024	lincoln park capital fund, llc	676%	1,307,049	SC 13G/A
Feb 14, 2024	lytton laurence w	9.99%	3,280,178	SC 13G/A
Feb 07, 2024	hirschman orin	8.7%	2,662,324	SC 13G/A
Jan 31, 2024	adar1 partners, lp	6.21%	1,824,063	SC 13G
Dec 07, 2023	lytton laurence w	9.99%	1,885,073	SC 13G
Dec 05, 2023	hirschman orin	9.9%	1,915,220	SC 13G
Feb 14, 2023	rosalind advisors, inc.	9.9%	986,293	SC 13G/A

Recent SEC filings of Cellectar Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 25, 2024	SC 13G/A	Major Ownership Report
Apr 01, 2024	10-K/A	Annual Report
Mar 27, 2024	8-K	Current Report
Mar 27, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Cellectar Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Cellectar Biosciences Inc News

Latest updates

Cellectar Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2011Q4	2011Q3	2011Q2	2011Q1	2010Q4	2009Q4
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	44,479	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-44.0%	12.00	22.00	7.00	15.00	22.00	19.00	26.00	32.00	37.00	42.00	48.00	55.00	59.00	21.00	24.00	9.00	12.00	16.00	19.00	13.00	15.00
Current Assets	-48.0%	10.00	20.00	6.00	14.00	21.00	19.00	25.00	31.00	37.00	41.00	47.00	54.00	58.00	20.00	23.00	8.00	11.00	15.00	18.00	11.00	14.00
Cash Equivalents	-49.6%	10.00	19.00	5.00	13.00	20.00	18.00	25.00	31.00	36.00	40.00	47.00	54.00	57.00	19.00	22.00	7.00	11.00	13.00	17.00	10.00	13.00
Net PPE	22.0%	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-20.9%	13.00	17.00	7.00	8.00	6.00	7.00	6.00	5.00	4.00	3.00	4.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00
Current Liabilities	-21.5%	13.00	16.00	6.00	7.00	6.00	7.00	6.00	5.00	4.00	3.00	4.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
Shareholder's Equity	-Infinity%	-1.36	-	-	7.00	16.00	13.00	20.00	27.00	33.00	39.00	44.00	50.00	55.00	16.00	20.00	5.00	9.00	12.00	16.00	10.00	13.00
Retained Earnings	-3.5%	-217	-210	-196	-	-179	-172	-164	-	-150	-144	-139	-133	-126	-123	-119	-115	-111	-108	-104	-101	-97.59
Additional Paid-In Capital	7.6%	210	195	194	194	194	184	183	183	183	182	175	171	162	138	138	120	120	119	119	109	108
Shares Outstanding	109.1%	21.00	10.00	10.00	10.00	9.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	19.00	-	-	-	24.00	-	-	-	65.00	-	-	-	32.00	-	-	-	20.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-18.9%	-9,595	-8,067	-7,529	-7,183	-7,411	-7,013	-5,757	-5,039	-4,511	-6,429	-6,876	-4,752	-3,868	-3,502	-3,049	-3,512	-2,681	-3,544	-2,652	-2,815	-2,743
Share Based Compensation	117.8%	1,084	498	420	408	361	368	420	304	378	421	201	125	114	116	93.00	144	208	150	301	208	208
Cashflow From Investing	-Infinity%	-266	-	-	-	-117	-7.07	-70.98	-30.07	-129	-4.06	-	-	-17.21	-	-34.59	-10.55	-5.72	-3.09	-9.48	-6.24	-373
Cashflow From Financing	-98.0%	441	22,499	-	3*	-	-	-	-	-1*	-	35.00	1,214	42,209	-106	18,443	-	-	-568*	9,024	-811*	-790*

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLRB Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
COSTS AND EXPENSES:
Research and development	$ 28,211,460	$ 19,219,603
General and administrative	10,749,183	9,594,170
Total costs and expenses	38,960,643	28,813,773
LOSS FROM OPERATIONS	(38,960,643)	(28,813,773)
OTHER INCOME (EXPENSE):
Warrant issuance expense	(470,000)
Gain on valuation of warrants	1,000,000
Interest income, net	387,147	152,519
Total other income, net	917,147	152,519
LOSS BEFORE INCOME TAXES	(38,043,496)	(28,661,254)
INCOME TAX BENEFIT	(60,000)	(60,000)
NET LOSS	$ (37,983,496)	$ (28,601,254)
BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	$ (3.11)	$ (4.05)
DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	$ (3.11)	$ (4.05)
SHARES USED IN COMPUTING BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	12,221,571	7,055,665
SHARES USED IN COMPUTING DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE	12,221,571	7,055,665

CLRB Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 9,564,988	$ 19,866,358
Prepaid expenses and other current assets	888,225	663,243
Total current assets	10,453,213	20,529,601
Fixed assets, net	1,090,304	418,641
Right-of-use asset, net	502,283	560,334
Long-term assets	23,566	75,000
Other assets	6,214	6,214
TOTAL ASSETS	12,075,580	21,589,790
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	9,178,645	5,478,443
Warrant liability	3,700,000
Lease liability	58,979	50,847
Total current liabilities	12,937,624	5,529,290
Lease liability, net of current portion	494,003	552,981
TOTAL LIABILITIES	13,431,627	6,082,271
COMMITMENTS AND CONTINGENCIES (Note 10)
STOCKHOLDERS' (DEFICIT) EQUITY:
Common stock, $0.00001 par value; 170,000,000 shares authorized; 20,744,110 and 9,385,272 shares issued and outstanding as of December 31, 2023 and 2022, respectively	207	94
Additional paid-in capital	210,066,630	193,624,445
Accumulated deficit	(217,482,539)	(179,499,043)
Total stockholders' (deficit) equity	(1,356,047)	15,507,519
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	12,075,580	21,589,790
Series D preferred stock
STOCKHOLDERS' (DEFICIT) EQUITY:
Preferred stock	1,382,023	$ 1,382,023
Series E-2 Preferred Stock
STOCKHOLDERS' (DEFICIT) EQUITY:
Preferred stock	$ 4,677,632

About Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CEO	Mr. James V. Caruso
WEBSITE	cellectar.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Cellectar Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Cellectar Biosciences Inc? What does CLRB stand for in stocks?

CLRB is the stock ticker symbol of Cellectar Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cellectar Biosciences Inc (CLRB)?

As of Thu May 02 2024, market cap of Cellectar Biosciences Inc is 107.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLRB stock?

You can check CLRB's fair value in chart for subscribers.

What is the fair value of CLRB stock?

You can check CLRB's fair value in chart for subscribers. The fair value of Cellectar Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cellectar Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLRB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cellectar Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CLRB is over valued or under valued. Whether Cellectar Biosciences Inc is cheap or expensive depends on the assumptions which impact Cellectar Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLRB.

What is Cellectar Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, CLRB's PE ratio (Price to Earnings) is -2.84 and Price to Sales (PS) ratio is 44.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLRB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cellectar Biosciences Inc's stock?

In the past 10 years, Cellectar Biosciences Inc has provided -0.422 (multiply by 100 for percentage) rate of return.